Wednesday, October 17, 2018
5% more people given PCSK9 inhibitor evolocumab (Repatha) died from cardiovascular causes
5% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died from cardiovascular causes during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.
251 people (out of 13,784) given evolocumab died compared to 240 people (out of 13,780) given a placebo.
So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?
No, thank you.Read the entire article | Email this article
Wednesday, November 12, 2008
People who wore pedometers increased daily steps from 6779 to 8855
QUICKLINKS AND VIEW OPITONS
QUOTE OF THE DAY
Books by Larry Hobbs available on Amazon
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.